MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries https://shar.es/agmcHm #TB #access2meds #patent
MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries
MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versionsMédecins Sans Frontières Access Campaign
